Equities

ALCAR

FR0010907956

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:35:11 2024-05-20 am EDT			After market 01:53:02 pm
3.04 ^EUR	-1.78%		3.035	-0.16%

May. 17	Oddo BHF Cuts Carmat PT, Affirms Neutral Rating	MT
May. 17	CARMAT : price target lowered by Oddo BHF	CF

Carmat SA Reports Earnings Results for the Full Year Ended December 31, 2023

April 29, 2024

Carmat SA reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was EUR 18.6 million compared to EUR 9 million a year ago. Net loss was EUR 53.87 million compared to EUR 53.68 million a year ago.

Latest news about CARMAT

Oddo BHF Cuts Carmat PT, Affirms Neutral Rating	May. 17	MT
CARMAT : price target lowered by Oddo BHF	May. 17	CF
Carmat Raises EUR16 Million for Ongoing Operations, Clinical Trial	May. 17	MT
Carmat: 16 million euros successfully raised	May. 17	CF
Carmat: launches a fund-raising campaign of around €15 million	May. 16	CF
Carmat: progress in ongoing clinical study	May. 06	CF
CARMAT Continues to Build on Its Momentum in the EFICAS Study	May. 06	CI
Carmat SA Reiterates Sales Guidance for the Year 2024	May. 06	CI
Carmat SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Carmat: final agreement with creditors	Mar. 25	CF
Carmat Secures Two-year Extensions for Bank Loans	Mar. 25	MT
CARMAT Announces a Final Agreement with All Its Financial Creditors on New Repayment Terms for Its Bank Loans	Mar. 22	CI
Carmat: up sharply, broker upgrades to 'buy	Feb. 01	CF
CARMAT : Invest Securities upgrades to 'buy'.	Feb. 01	CF
Oddo BHF Keeps Carmat at Neutral, Cuts PT	Jan. 29	MT
France’s Carmat Secures EUR17 Million via Capital Raise; Shares Fall	Jan. 29	MT
CARMAT : price target lowered by Oddo BHF	Jan. 29	CF
Carmat: capital increase completed	Jan. 29	CF
Carmat SA announced that it has received ?16.5186 million in funding	Jan. 28	CI
CARMAT : Invest Securities advises to subscribe	Jan. 18	CF
Transcript : Carmat SA - Special Call	Jan. 17
Carmat: launches a capital increase	Jan. 17	CF
Carmat SA announced that it expects to receive ?15.000002 million in funding	Jan. 16	CI
Carmat: has passed the 50-implant milestone	Jan. 15	CF
Artificial heart maker Carmat to launch capital increase soon	Jan. 15	RE

Chart CARMAT

Duration

Period

More charts

Company Profile

CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for CARMAT

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.095 EUR

Average target price

12.98 EUR

Spread / Average Target

+319.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
CARMAT	-54.63%	97.98M
STRYKER CORPORATION	+10.24%	127B
SMITH & NEPHEW PLC	-5.15%	11.34B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+6.07%	9.11B
GLAUKOS CORPORATION	+37.35%	5.53B
AXONICS, INC.	+8.55%	3.45B
ENOVIS CORPORATION	-8.39%	2.87B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-6.38%	2.1B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-10.91%	2.08B
DOUBLE MEDICAL TECHNOLOGY INC.	-23.21%	1.78B

Medical Devices & Implants